Canopy Immuno-Therapeutics
Canopy Immuno-Therapeutics
Stealth ModeStealth biotech developing novel immunotherapies for autoimmunity and life-threatening allergies.
Rate
About
Canopy Immuno-Therapeutics is developing antigen-drug conjugates (AgDCs) as a novel, non-immunosuppressive, and potentially curative therapy for antibody-mediated autoimmune diseases. Their AgDCs specifically target and eliminate pathological antibodies and autoreactive B-cells, preserving protective immunity.
Technology stack
detected 2026-06-25Email
Google Workspace
Hosting
self_managed
Stack
jQuery
WordPress
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does Canopy Immuno-Therapeutics do?
Canopy Immuno-Therapeutics is developing antigen-drug conjugates (AgDCs) as a novel, non-immunosuppressive, and potentially curative therapy for antibody-mediated autoimmune diseases. Their AgDCs specifically target and eliminate pathological antibodies and autoreactive B-cells, preserving protective immunity.
When was Canopy Immuno-Therapeutics founded?
Canopy Immuno-Therapeutics was founded in 2019.
What industry does Canopy Immuno-Therapeutics operate in?
Canopy Immuno-Therapeutics operates in Life Sciences, Immunotherapy, Immunology, Biotech, Drug Discovery, Autoimmunity.
What is Canopy Immuno-Therapeutics's current status?
Canopy Immuno-Therapeutics's current operating status is: Inactive.